Invention Grant
- Patent Title: Tricyclic heterocycles as FGFR inhibitors
-
Application No.: US17835331Application Date: 2022-06-08
-
Publication No.: US11939331B2Publication Date: 2024-03-26
- Inventor: Xin Li , Evan Styduhar , Robert Swyka , Oleg Vechorkin , Wenqing Yao
- Applicant: Incyte Corporation
- Applicant Address: US DE Wilmington
- Assignee: Incyte Corporation
- Current Assignee: Incyte Corporation
- Current Assignee Address: US DE Wilmington
- Agency: Fish & Richardson P.C.
- Main IPC: C07D471/14
- IPC: C07D471/14 ; A61K31/4375 ; A61K31/439 ; A61K31/496 ; A61K31/506 ; A61K31/5377 ; A61K31/541 ; A61P35/00 ; C07D519/00
Abstract:
The present disclosure relates to tricyclic heterocycles, and pharmaceutical compositions of the same, that are inhibitors of the FGFR enzyme and are useful in the treatment of FGFR-associated diseases such as cancer.
Public/Granted literature
- US20230002385A1 TRICYCLIC HETEROCYCLES AS FGFR INHIBITORS Public/Granted day:2023-01-05
Information query
